Results 331 to 340 of about 857,410 (384)

Multiple and Alternative Sites Make Tau Protein an Adaptable Sticky Surface for the SH3 Domain of Fyn Kinase

Angewandte Chemie, EarlyView.
An NMR‐based study, combined with computational, calorimetric and in‐cell FRET methods, sheds light on the complex recognition mechanism between the intrinsically disordered protein Tau and the SH3 domain of Fyn kinase, highlighting how the multiple binding sites present in Tau make the protein an adaptable recognition surface that can function even ...
Roberto Tira, Giulia Leo, Laura Prandini, Carlo Giorgio Barracchia, Mariapina D'Onofrio, Luca Mollica, Stefano Capaldi, Michael Assfalg, Francesca Munari   +8 more
wiley   +1 more source

Access to N‐Monofluoromethylated (Thio)Carbamates, Formamides, Alkynamides, and Related Derivatives

Angewandte Chemie, EarlyView.
The first general synthetic access to N‐CH₂F and N‐CHRF carbamates, thiocarbamates, formamides, alkynamides, and related compounds is disclosed. The method involves the direct synthesis of carbamoyl fluoride building blocks from readily available amines, followed by their derivatization. Abstract This work presents the first general synthetic access to
Filip G. Zivkovic, Fritz Bahns, Che‐Ming Hsu, Franziska Schoenebeck   +3 more
wiley   +1 more source

Remimazolam induced cytotoxicity mediated through multiple stress pathways and acted synergistically with tyrosine kinase inhibitors in hepatocellular carcinoma. [PDF]

Redox Rep
Fan HL, Chen JL, Liu ST, Lee JT, Huang SM, Wu ZF, Lai HC.   +6 more
europepmc   +1 more source

The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma. [PDF]

BMC Cancer
Deng W, Xie J, Wang T, Luo L, Zhu G, Xiao Y, Tao J, Lin L, Ge X, Wen W, Wang M, Yu B, Liu Y, Luo R, Wan R, Hu Z, Shan R.   +16 more
europepmc   +1 more source

Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors. [PDF]

Pharmaceuticals (Basel)
Wan Z, Wang C, Luo S, Zhu J, He H, Hao K.   +5 more
europepmc   +1 more source

Living with chronic myelogenous leukemia in rural communities: Exploring factors related to tyrosine kinase inhibitors adherence with a mixed methods approach. [PDF]

J Rural Health
Sheng J, Heiney SP, Wickersham KE, Nguyen LA, Harrison KW, Adams SA.   +5 more
europepmc   +1 more source

Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells. [PDF]

Oncol Res
Modi SR, Andey T.
europepmc   +1 more source

Assessment of Treatment Outcome in Chronic Myelogenous Leukemia Patients on Tyrosine Kinase Inhibitors: Insight From a Resource Limited Setting. [PDF]

Cancer Med
Awlachew WY, Tasamma AT, Mengistie FA, Alemineh ZT, Tefera ST.   +4 more
europepmc   +1 more source